Trial Profile
Phase ll trial of Amrubicin in Patients with Previously Treated Advanced Squamous Cell Lung Cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2013
Price :
$35
*
At a glance
- Drugs Amrubicin (Primary)
- Indications Lung cancer
- Focus Therapeutic Use
- 25 Jun 2013 Status changed from recruiting to discontinued, as reported by University Hospital Medical Information Network - Japan record (UMIN000006370).
- 28 Mar 2012 Planned end date changed from 1 Sep 2013 to 1 Sep 2014 as reported by University Hospital Medical Information Network - Japan (UMIN000004235).
- 19 Dec 2011 Additional lead trial centre added as reported by University Hospital Medical Information Network - Japan.